Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT7AKW1)

DTT Name T-cell receptor (TCR)
Gene Name TCR
DTT Type
Clinical trial target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T82494

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tebentafusp DMUJ1WV Gastric cancer 2B72 Approved [2]
------------------------------------------------------------------------------------
8 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IR502 DMW2IF9 Plaque psoriasis EA90.0 Phase 2 [3]
RGI-2001 DM4AC2F Graft-versus-host disease 4B24 Phase 2 [4]
SAR444200 DM7J5H0 Aggressive cancer 2A00-2F9Z Phase 2 [5]
MAGE-A10 TCR DM6H3YS Bladder cancer 2C94 Phase 1/2 [2]
NY-ESO-TCR DMS0L6J Melanoma 2C30 Phase 1/2 [2]
TOL-101 DM6AXV9 Multiple sclerosis 8A40 Phase 1/2 [1]
AFP TCR DMHBUMZ Hepatocellular carcinoma 2C12.02 Phase 1 [2]
BPX-701 DMYERSD Acute myeloid leukaemia 2A60 Phase 1 [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Clinical Trial Drug(s)

References

1 First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 WO patent application no. 2004,0677,06, Production of multimeric proteins.
4 Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
5 Clinical pipeline report, company report or official report of Sanofi